Table 2.

Tumor characteristics of patients with COVID-19 pneumonia.

Variables	All n = 70	<14% extent n = 38	14–30% extent n = 23	≥30% extent n = 9	P-value
Cancer					0.83
Breast	27 (38%)	17 (45%)	7 (30%)	3 (34%)
Lung	11 (16%)	6 (16%)	5 (22%)	0 (0%)
Hemopathy	5 (7%)	2 (5%)	2 (9%)	1 (11%)
Gynecologic	6 (9%)	4 (10%)	1 (4%)	1 (11%)
GI	9 (13%)	3 (8%)	4 (17.5%)	2 (22%)
Others	12 (17%)	6 (16%)	4 (17.5%)	2 (22%)
PS					0.26
<2	43 (61%)	27 (71%)	12 (52%)	4 (44%)
≥2	27 (39%)	11 (29%)	11 (48%)	5 (56%)
Stage					0.99
Local	22 (31%)	12 (32%)	7 (30%)	3 (33%)
Metastatic	48 (69%)	26 (68%)	16 (70%)	6 (67%)
Metastatic site
Lung	17/48 (35%)	9/26 (35%)	5/16 (31%)	3/6 (50%)	0.71
Brain	8/48 (17%)	4/26 (15%)	4/16 (25%)	0/6 (0%)	0.36
Liver	14/48 (29%)	5/26 (19%)	7/16 (44%)	2/6 (33%)	0.23
Bone	20/48 (42%)	10/26 (39%)	5/16 (31%)	4/6 (67%)	0.31
Peritoneum	5/48 (10%)	2/26 (8%)	1/16 (6%)	2/6 (33%)	0.14
Number of lines of treatment					0.23
<3	41/48 (85%)	24/26 (92%)	13/16 (81%)	4/6 (67%)
≥3	7/48 (15%)	2/26 (8%)	3/16 (19%)	2/6 (33%)
Oncologic treatment
Surgery	1 (1%)	1 (3%)	0 (0%)	0 (0%)	0.65
Chemotherapy	27 (39%)	14 (37%)	10 (44%)	3 (33%)	0.74
Targeted or endocrine therapies	12 (17%)	10 (26%)	2 (9%)	0 (0%)	0.07
Immunotherapy	3 (4%)	2 (5%)	1 (4%)	0 (0%)	0.78
Radiotherapy	2 (3%)	1 (3%)	0 (0%)	1 (11%)	0.24
Regular treatment
Corticosteroids	18 (26%)	9 (24%)	6 (26%)	3 (33%)	0.59
NSAID	3 (4%)	2 (5%)	1.0 (4%)	0 (0%)	0.52
Anticoagulants	8 (11%)	1 (3%)	6 (26%)	1 (11%)	0.02

Data are expressed as n (%). Corticosteroids refer to a chronic daily dose equivalent to ≥10 mg of prednisolone (chemotherapy premedication was not taken into account); PS, performance status; NSAID, non-steroidal anti-inflammatory drugs.

Bold p-values were considered statistically significant (p < 0.05).